RecruitingNCT06229860

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia

Sponsor

University of California, Irvine

Enrollment

75 participants

Start Date

Jan 25, 2024

Study Type

OBSERVATIONAL

Conditions

Chronic Myeloid Leukemia Chronic Phase Chronic Myelogenous Leukemia

Summary

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring how personality traits influence whether patients with chronic myeloid leukemia (CML) take their oral cancer medication consistently. The goal is to use this knowledge to improve medication adherence. **You may be eligible if...** - You are 18 or older diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP) - You are currently being treated with imatinib, dasatinib, bosutinib, or nilotinib - You are a patient at the UCI Chao Family Comprehensive Cancer Center, OR a member of the CML Buster Foundation patient support group **You may NOT be eligible if...** - You cannot read and speak English - You have impaired ability to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.